Abstract: A compute device can access local or remote accelerator devices for use in processing a received packet. The received packet can be processed by any combination of local accelerator devices and remote accelerator devices. In some cases, the received packet can be encapsulated in an encapsulating packet and sent to a remote accelerator device for processing. The encapsulating packet can indicate a priority level for processing the received packet and its associated processing task. The priority level can override a priority level that would otherwise be assigned to the received packet and its associated processing task. The remote accelerator device can specify a fullness of an input queue to the compute device. Other information can be conveyed by packets transmitted between and among compute devices and remote accelerator devices to assist in determining an accelerator to use or other uses.

Abstract: A shared networking pipeline is implemented by a network interface device and shared by a plurality of host devices. A pool of shared buffers of a network interface device correspond to one or more stages in the pipeline and are configured to allocate entries to the plurality of host devices based on the respective shares of the shared packet processing pipeline. Data is buffered associated with traffic of a first one of the plurality of host devices in a first subset of shared buffers, where the traffic is to proceed from a first stage to a second stage in the shared packet processing pipeline, and the data is associated with processing of the traffic by the second stage. Forward progress of the traffic is to be prevented from the first stage to the second stage when the first subset of entries are occupied.

Abstract: A compute device can access local or remote accelerator devices for use in processing a received packet. The received packet can be processed by any combination of local accelerator devices and remote accelerator devices. In some cases, the received packet can be encapsulated in an encapsulating packet and sent to a remote accelerator device for processing. The encapsulating packet can indicate a priority level for processing the received packet and its associated processing task. The priority level can override a priority level that would otherwise be assigned to the received packet and its associated processing task. The remote accelerator device can specify a fullness of an input queue to the compute device. Other information can be conveyed by packets transmitted between and among compute devices and remote accelerator devices to assist in determining an accelerator to use or other uses.

Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.

Abstract: Systems and techniques for processing and/or forwarding packets are described. An ingress switch can use a QoS mapping mechanism to map a first set of Quality of Service (QoS) bits in a packet received from a customer to a second set of QoS bits for use in a Transparent Interconnection of Lots of Links (TRILL) packet which encapsulates the packet. The first set of QoS bits can be different from the second set of QoS bits. The TRILL packet can be processed and/or forwarded in the network based on the second set of QoS bits. At the egress switch, the TRILL packet can be decapsulated and the original packet with the original QoS bits (or QoS bits that are different from the original QoS bits) can be forwarded to the customer's network. In this manner, some embodiments of the present invention can preserve the QoS bits across a TRILL network.

Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.

Abstract: One embodiment of the present invention provides a switch. The switch includes a forwarding mechanism and a control mechanism. During operation, the forwarding mechanism forwards frames based on their Ethernet headers. The control mechanism operates the switch in conjunction with a separate physical switch as a single logical switch and assigns a virtual switch identifier to the logical switch, wherein the virtual switch identifier is associated with a link aggregation group.

Abstract: A LPM search engine includes a plurality of exact match (EXM) engines and a moderately sized TCAM. Each EXM engine uses a prefix bitmap scheme that allows the EXM engine to cover multiple consecutive prefix lengths. Thus, instead of covering one prefix length L per EXM engine, the prefix bitmap scheme enables each EXM engine to cover entries having prefix lengths of L, L+1, L+2 and L+3, for example. As a result, fewer EXM engines are potentially underutilized, which effectively reduces quantization loss. Each EXM engine provides a search result with a determined fixed latency when using the prefix bitmap scheme. The results of multiple EXM engines and the moderately sized TCAM are combined to provide a single search result, representative of the longest prefix match. In one embodiment, the LPM search engine supports 32-bit IPv4 (or 128-bit IPv6) search keys, each having associated 15-bit level 3 VPN identification values.

Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac

Abstract: A solution for network packet latency measurement includes, at a network device having a memory, storing a first time value indicating when an ingress port of the network device received a packet. The solution also includes storing a second time value indicating when an egress port of the network device received the packet for transmission towards another network device. The solution also includes storing a difference between the first time value and the second time value.

Abstract: One embodiment of the present invention provides a switch. The switch includes a forwarding mechanism and a control mechanism. During operation, the forwarding mechanism forwards frames based on their Ethernet headers. The control mechanism operates the switch in conjunction with a separate physical switch as a single logical switch and assigns a virtual switch identifier to the logical switch, wherein the virtual switch identifier is associated with a link aggregation group.

Abstract: A LPM search engine includes a plurality of exact match (EXM) engines and a moderately sized TCAM. Each EXM engine uses a prefix bitmap scheme that allows the EXM engine to cover multiple consecutive prefix lengths. Thus, instead of covering one prefix length L per EXM engine, the prefix bitmap scheme enables each EXM engine to cover entries having prefix lengths of L, L+1, L+2 and L+3, for example. As a result, fewer EXM engines are potentially underutilized, which effectively reduces quantization loss. Each EXM engine provides a search result with a determined fixed latency when using the prefix bitmap scheme. The results of multiple EXM engines and the moderately sized TCAM are combined to provide a single search result, representative of the longest prefix match. In one embodiment, the LPM search engine supports 32-bit IPv4 (or 128-bit IPv6) search keys, each having associated 15-bit level 3 VPN identification values.

Abstract: A method for detecting one or more metabolites of a test agent in a tissue including: A) incubating a test agent and an enzyme within a three-dimensional structure comprising a first mold or polymer scaffold, a semi-permeable membrane, and a second mold or polymer scaffold, wherein the semi-permeable membrane is disposed between the first and second molds or polymer scaffolds, and wherein the first mold or polymer scaffold has microchannels that form a fluidic branching network that mimics the forces and transport of natural vasculatures and wherein the second mold or polymer scaffold comprises cells; B) forming an enzyme-substrate complex between the enzyme and the test agent; and C) detecting one or more metabolites of the test agent.

Abstract: A memory system including a content addressable memory (CAM) array and a non-CAM array. The non-CAM array, which may share word lines with the CAM array, stores one or more error detection bits associated with each row of the CAM array. A state machine reads entries of the CAM array and corresponding error detection bits of the non-CAM array during idle cycles of the CAM array. Error detection logic identifies errors in the entries read from CAM array (using the retrieved error detection bits). If these errors are correctable, the error detection logic corrects the entry, and writes the corrected entry back to the CAM array (an updated set of error detection bits are also written to the non-CAM array). If these errors are not correctable, an interrupt is generated, which causes correct data to be retrieved from a shadow copy of the CAM array.

Abstract: A solution for network packet latency measurement includes, at a network device having a memory, storing a first time value indicating when an ingress port of the network device received a packet. The solution also includes storing a second time value indicating when an egress port of the network device received the packet for transmission towards another network device. The solution also includes storing a difference between the first time value and the second time value.

Abstract: One embodiment of the present invention provides a switch. The switch includes a forwarding mechanism and a control mechanism. During operation, the forwarding mechanism forwards frames based on their Ethernet headers. The control mechanism operates the switch in conjunction with a separate physical switch as a single logical switch and assigns a virtual switch identifier to the logical switch, wherein the virtual switch identifier is associated with a link aggregation group.

Abstract: Systems and techniques for processing and/or forwarding packets are described. An ingress switch can use a QoS mapping mechanism to map a first set of Quality of Service (QoS) bits in a packet received from a customer to a second set of QoS bits for use in a Transparent Interconnection of Lots of Links (TRILL) packet which encapsulates the packet. The first set of QoS bits can be different from the second set of QoS bits. The TRILL packet can be processed and/or forwarded in the network based on the second set of QoS bits. At the egress switch, the TRILL packet can be decapsulated and the original packet with the original QoS bits (or QoS bits that are different from the original QoS bits) can be forwarded to the customer's network. In this manner, some embodiments of the present invention can preserve the QoS bits across a TRILL network.

Abstract: Systems and techniques for processing and forwarding packets are described. Some embodiments provide a system (e.g., a switch) which determines an internal virtual network identifier and/or an internal policy identifier for a packet based on a port on which the packet was received and/or one or more fields in the packet. The system can then process and forward the packet based on the internal virtual network identifier and/or internal policy identifier. In some embodiments, the system encapsulates the packet in a TRILL (Transparent Interconnection of Lots of Links) packet by adding a TRILL header to the packet. In some embodiments, the scope of an internal virtual network identifier and/or an internal policy identifier may not extend beyond a switch or a module within a switch.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalac